Loyal is developing pharmaceuticals that target metabolic dysfunction and hormonal imbalances in aging dogs, specifically those aged 7 and older. Their products aim to extend healthy lifespan and improve quality of life by delaying the onset of age-associated diseases.
Funding
$45M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
+1Founders
Product
Problem
As dogs age, they often experience metabolic dysfunction and hormonal imbalances, leading to age-associated diseases that diminish their quality of life and shorten their healthy lifespan. Current veterinary medicine lacks preventative therapies specifically designed to address the underlying causes of aging in dogs.
Solution
Loyal is developing pharmaceutical interventions that target the root causes of aging in dogs, aiming to extend their healthy lifespan and improve overall well-being. Their therapies focus on preventing and delaying the onset of age-related diseases by addressing metabolic dysfunction and hormonal imbalances. By intervening at the biological level, Loyal strives to help dogs live longer, healthier lives, maintaining their vitality and quality of life as they age.
Target Audience
The primary target audience includes senior dogs, particularly large breeds aged 7 and older, and their owners who are seeking to extend their pets' healthy lifespan and improve their quality of life. Veterinary professionals are also a key audience, as they will administer and recommend these therapies to their patients.
Features
- LOY-002: Designed for senior dogs of nearly all sizes to correct metabolic dysfunction, projected availability in 2025.
- LOY-001 and LOY-003: Formulated for large dogs aged 7 and older to correct overexpression of IGF-1 and growth hormone (GH) post-maturity, projected availability in 2027.
- Preventative care approach addressing the underlying causes of age-associated diseases.
- Participation in the STAY clinical study for LOY-002, enrolling 1,000 senior dogs across the country.